Trial Profile
A prospective trial to evaluate the effect of Imatinib, Nilotinib and Dasatinib on the pulmonary hypertension of patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Pulmonary hypertension
- Focus Therapeutic Use
- 25 Jun 2017 Results of comparative analysis (n=105) presented at the 22nd Congress of the European Haematology Association.
- 02 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.